GlassScriptPhysician profile
Abdallah Amireh
NPI 1538681903
$2,712.36
in general payments reported to CMS, 2019-2025
15 companies · $337 in 2025
The $337 reported for 2025 was less than what a typical Vascular Neurology provider received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $124 · 2021: $33.58 · 2022: $576 · 2023: $1,116 · 2024: $525 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,525 · Travel and Lodging: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,525.21 |
| Travel and Lodging | $453.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,408.80 | 2022-2024 | Target, Trevo, Neuroform Atlas |
| Depuy Synthes Sales INC. | $290.91 | 2024-2025 | Embotrap, Trufill |
| Route 92 Medical, INC. | $191.69 | 2024-2025 | 8f Base Camp Sheath System |
| Qapel Medical INC | $174.69 | 2024-2025 | |
| Boston Scientific Corporation | $126.96 | 2023 | |
| Alexion Pharmaceuticals, INC. | $124.47 | 2020 | |
| Celgene Corporation | $115.54 | 2023-2024 | Zeposia |
| Abbvie INC. | $61.59 | 2022-2024 | Ubrelvy |
| Imperative Care, INC | $49.46 | 2025 | Zoom 7x Catheter |
| Becton, Dickinson and Company | $43.29 | 2025 | Hemosphere |
| Astrazeneca Pharmaceuticals LP | $33.49 | 2021-2023 | Andexxa |
| Microtransponder, INC. | $33.09 | 2025 | |
| Genzyme Corporation | $26.05 | 2025 | |
| Genentech, INC. | $18.58 | 2021 | |
| Inari Medical, INC. | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdallah Amireh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.